Trials / Unknown
UnknownNCT00798148
131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma
Evaluation of Benefit and Side Effects of 131I-MIBG in Combination With Myeloablative Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Tehran University of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 1 Year – 14 Years
- Healthy volunteers
- Not accepted
Summary
This trial is studying how well iodine I 131 metaiodobenzylguanidine together with combination chemotherapy works in treating patients who are undergoing an autologous peripheral stem cell for high risk or relapsed neuroblastoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 131I-MIBG , Etoposide, Melphalan, Carboplatin, Autologous Peripheral Stem Cell Transplantation | 131I-MIBG 12mci/kg CEM(Etoposide)=1200mg/m2 Melphalan=210mg/m2 Carboplatin=1500mg/m2 Autologous Peripheral Stem Cell Transplantation |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2012-07-01
- First posted
- 2008-11-25
- Last updated
- 2012-06-04
Locations
2 sites across 1 country: Iran
Source: ClinicalTrials.gov record NCT00798148. Inclusion in this directory is not an endorsement.